Panel Community Conversations track
Pediatric Metabolic Dysfunction–Associated Steatotic Liver Disease Pharmacotherapy: Pathways to Regulatory Approval
Sat, Nov 7, 2026 · 3:45–4:45 PM MST Convention Center: Bluebird Ballroom 3GH, Colorado Convention Center
About this session
Metabolic dysfunction–associated steatotic liver disease (MASLD) is now the most common chronic liver disease in children. Yet no pharmacotherapies are currently approved for pediatric use. Despite rapid advances in adult MASLD/metabolic dysfunction–associated steatohepatitis (MASH) drug development, translation/extrapolation to pediatric populations remains limited due to biologic differences, ethical considerations, feasibility challenges, and regulatory uncertainty.
